750 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Gordian Capital Singapore Pte Ltd

Key Points

• Gordian Capital Singapore Pte Ltd acquired 750 shares of IDEXX Laboratories, Inc., totaling approximately $312,000, marking their new position in the company.
• Multiple hedge funds, including MorganRosel Wealth Management LLC and Bank of Jackson Hole Trust, have recently increased their stakes in IDEXX Laboratories, indicating growing institutional interest.
• IDEXX Laboratories has received positive analyst ratings recently, with BTIG Research raising its target price from $545 to $785, reflecting a bullish outlook for the stock.

Gordian Capital Singapore Pte Ltd bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 750 shares of the company's stock, valued at approximately $312,000.

Other hedge funds also recently bought and sold shares of the company. MorganRosel Wealth Management LLC bought a new stake in IDEXX Laboratories in the 1st quarter worth approximately $26,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after buying an additional 30 shares during the last quarter. Colonial Trust Co SC lifted its position in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the last quarter. WPG Advisers LLC bought a new stake in IDEXX Laboratories in the 1st quarter worth approximately $37,000. Finally, Bank of Jackson Hole Trust lifted its position in IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after buying an additional 69 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. BTIG Research boosted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Piper Sandler reaffirmed a "neutral" rating and issued a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research note on Monday, August 4th. Finally, Leerink Partners upped their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $649.44.

Insider Activity

In other news, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company's stock, valued at approximately $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares in the company, valued at $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

IDXX opened at $647.03 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The stock has a market capitalization of $51.76 billion, a PE ratio of 53.87, a price-to-earnings-growth ratio of 4.15 and a beta of 1.49. The stock's 50 day moving average price is $579.57 and its 200-day moving average price is $498.92.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the previous year, the firm earned $2.44 earnings per share. The business's revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.